A New Horizon for ALS? Masitinib Data Shows Unprecedented Survival Rates

PARIS, FRANCE – June 09, 2026 – In the relentless fight against amyotrophic lateral sclerosis (ALS), a disease defined by its grim prognosis, glimmers of hope are precious commodities. Today, French pharmaceutical firm AB Science offered more than a glimmer, announcing it will present stunning long-term survival data for its drug, masitinib, that suggests a potential paradigm shift in treating the devastating neurodegenerative condition.

The new analysis, slated for presentation at the prestigious 2026 European Network to Cure ALS (ENCALS) annual meeting, indicates that treatment with masitinib could nearly double the five-year survival rate for patients, a milestone that has remained stubbornly out of reach for decades. For a community accustomed to incremental advances, this news lands with the force of a tectonic shift, blending profound hope with the requisite scientific caution.

A New Benchmark for Survival

For years, the statistics for ALS have painted a stark picture. The average life expectancy hovers between two to five years from diagnosis, with published registry data showing that only about 24% of patients, on average, survive to the five-year mark. Against this backdrop, the data from AB Science’s Phase 3 trial, AB10015, appears transformative.

The analysis reveals a five-year survival rate of 42.3% from symptom onset for patients treated with masitinib and the current standard-of-care drug, riluzole. This figure alone represents a dramatic leap beyond historical benchmarks. Perhaps even more importantly, the data speaks to a core concern for every patient and family: quality of life. The company reports that nearly half (49%) of these long-term survivors did so without needing mechanical support—meaning no permanent reliance on ventilation, feeding tubes, or a wheelchair. This suggests that a longer life does not have to mean a life of diminished functional independence.

“In study AB10015, the examination of long-term survivors seems to indicate a clinically relevant survival benefit for ALS patients receiving masitinib, when compared to historical standards,” commented Professor Albert Ludolph, Chairman of the Department of Neurology at the University Hospital and Medical Faculty of Ulm, who will present the findings. “Notably, half of these long-term survivors preserved a high quality of life, highlighting that prolonged survival does not necessarily compromise functional independence.”

The Science and the Scrutiny

Masitinib is a tyrosine kinase inhibitor, a class of drug that can precisely block cellular signaling pathways. Its proposed benefit in ALS stems from its ability to target mast cells and pro-inflammatory microglia, key actors in the neuroinflammation that contributes to motor neuron death. By calming this inflammatory storm in the nervous system, the therapy aims to slow the disease's destructive march. This targeted approach is a cornerstone of modern drug development, moving beyond symptom management to address the underlying mechanics of a disease.

However, this promising data arrives with a history. The road for masitinib in ALS has been neither short nor straight. In 2018, the European Medicines Agency’s (EMA) advisory committee recommended against approving the drug, citing concerns with the trial's primary analysis and conduct. This history makes Professor Ludolph's concluding remark all the more critical: “Additional confirmatory evidence is required to verify these encouraging results.”

The landscape of ALS drug development is littered with therapies that showed early promise only to fail in late-stage trials, a recent example being the market withdrawal of Relyvrio. Therefore, the scientific community will greet the full data set at the ENCALS meeting with a mixture of excitement and intense scrutiny. Experts will pore over the trial’s methodology, the statistical analysis, and the specific characteristics of the patient population to determine if this new long-term survival analysis is robust enough to overcome past reservations.

The Strategy of Early Intervention

Digging deeper into the data reveals a crucial strategic insight that is reshaping the future of neurodegenerative care: the profound impact of early intervention. The survival benefit of masitinib was even more pronounced in patients who began treatment before suffering severe functional decline. For patients who had not experienced a complete loss of functionality in any area at the trial's start, the five-year survival rate soared to 52.9%.

This finding powerfully underscores a growing consensus that the greatest opportunity to improve lives lies in acting early, preserving neurological function before it is irrevocably lost. This strategy is further bolstered by the company's reference to a recently identified biomarker that may help detect masitinib's effect on the pathological inflammation it is designed to treat. The convergence of a promising therapeutic with a potential biomarker to identify responsive patients early in their disease course represents a sophisticated and powerful approach. It's a strategy that could one day allow clinicians not just to treat ALS, but to treat the right patients at the right time to maximize their chances for a longer and better life.

Navigating the Path to Patients

For AB Science, this new analysis could be a pivotal moment, reigniting regulatory interest and investor confidence after previous setbacks. If the data withstands scientific peer review and is ultimately confirmed, masitinib would not be just another drug for ALS; it would be a foundational therapy that could redefine the standard of care. It offers the potential for a benefit that is not measured in months, but in years, and not just in survival, but in quality of life.

The upcoming presentation in Madrid is therefore more than just a scientific update; it is a critical test. The data must be compelling enough to convince regulators, clinicians, and patients that this time, the promise is real. For the thousands of people living with ALS and the families who support them, the stakes could not be higher as they watch and wait for what they hope will be a new dawn.